Supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.
Chronic kidney disease (CKD) in a complex disorder. Overactivation of the mineralocorticoid receptor plays a substantial role, with binding of aldosterone causing inflammation and fibrosis that leads to kidney disfunction. Targeting the mineralocorticoid receptor by blocking aldosterone was first explored in the 1930s, and in 1960 the first mineralocorticoid receptor antagonist, spironolactone, was introduced. The first of these agents were steroidal agents, and while they are still widely prescribed, they are associated with a number of adverse effects that limit their use. This prompted the search for nonsteroidal agents that target the mineralocorticoid receptor. Three agents (apararenone, esaxerenone, and finerenone) are furthest along in development. Nephrologists involved in the care of patients with CKD should be informed about the efficacy and safety profiles of these agents in order to be prepared for their potential approval by the US FDA. This educational activity will address this knowledge gap by providing a summary of the evolution of this class of agents and an overview of the phase 3 clinical data of the nonsteroidal agents, so that clinicians are able to provide optimal care for their patients with CKD.
Christos Argyropoulos, MD, PhD, FASN
Division Chief, Nephrology
University of New Mexico School of Medicine
Edgar Lerma, MD, FACP, FASN, FAHA, FASH,
FNLA, FNKF, FASDIN, FPSN (Hon)
Clinical Professor of Medicine
Section of Nephrology
University of Illinois at Chicago/
Advocate Christ Medical Center
Oak Lawn, IL
This educational activity has been designed to meet the needs of US-based nephrology healthcare professionals (HCPs), including nephrology physician assistants (PAs), nurse practitioners (NPs).
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of April 27, 2021 through April 27, 2022, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Physician Continuing Education
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or email@example.com.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices the have with ineligible companies related to the content of these CME activities:
Christos Argyropoulos, MD, PhD, FASN
Consulting Fees: Baxter, Bayer, HSAG
Contracted Research: Akebia
Edgar Lerma, MD, FACP, FASN, FAHA, FASH, FNLA, FNKF, FASDIN, FPSN (Hon)
Advisory Board: Bayer, Otsuka, AstraZeneca
Royalty: Wolters Kluwer, Springer, Elsevier, McGraw-Hill
Joint Venture: Fresenius
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Provided by Integrity Continuing Education, Inc.